National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

IL-2 recombinant fusion protein ALT-801
A recombinant protein consisting of the cytokine interleukin-2 (IL-2) fused to a humanized soluble T-cell receptor (TCR) directed against a tumor suppressor p53-derived antigen with potential immunopotentiating and antineoplastic activities. The TCR moiety of IL-2 recombinant fusion protein ALT-801 binds to tumor cells displaying p53 epitope/MHC complexes; subsequently, the tumor cell-localized IL-2 moiety may stimulate natural killer (NK) cell and T cell cytotoxic immune responses against p53-expressing tumor cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:ALT-801



Previous:Ifosfamidum, IGF-1R antagonist BMS-754807, IGF-1R inhibitor OSI-906, IH636 grape seed proanthocyanidin extract, IL-2 plasmid DNA/lipid complex
Next:IL-2/Lptn gene-modified allogeneic neuroblastoma tumor cell vaccine, iloprost, Ilotycin, Imagent, imatinib mesylate

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov